curasan AG (CUR) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 23 PAGES: 36

More Info
									             curasan AG (CUR) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDME13733FSA                                                                                           Publication Date: JUL 2013

          Lindigstrabe 4                                     Phone              +49 6027 409000                 Revenue          3.23 (million EUR)
          Kleinostheim                                       Fax                +49 6027 4090029                Net Profit       -3.47 (million EUR)
          63801                                              Website            www.curasan.de                  Employees        38
          Germany                                            Exchange           CUR [XETRA]                     Industry         Medical Equipment

       Company Overview
       curasan AG (curasan) develops, manufactures and commercializes products and services in the field of regenerative medicine.
       The company's product portfolio consists of synthetic bone substitutes, dental and bone regeneration material products. It offers
       these products under the Cerasorb, Ceracell, IngeniOs (formerly Osbone), Curavisc, stypro and advanced tissue regeneration
       (ATR)-curasan Set brand names. curasan offers these products to orthopedic and spinal surgeons, oral and maxillofacial
       surgeons, and periodontists and dental implantologists in the fields of bone and tissue regeneration, tissue engineering, and
       wound healing for dental, spinal and orthopedic applications.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      curasan AG, SWOT Analysis
         Hans Dieter Rossler                 Chairman                                 Strengths                              Weaknesses
         Dr. Fabian Peters                   Director, Technical
                                                                                      Product Offerings                      Dependence on End Market
         Dr. Wolf-Dietrich Hubner            Director, Medical
                                                                                      Research and Development               Financial Performance
         Dr. Erwin Amashaufer                Director, Commercial
         Lee McCann                          Director,      International
                                             Sales, Orthobiologics                    Opportunities                          Threats
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Emerging Economies                     Risk of Product Obsolescence

       Share Data                                                                     Product Launches                       Cost Containment Pressures
         curasan AG
        Share Price (EUR) as on 05-Jul-                                  2.25        Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        2013
        EPS (EUR)                                                       -0.51
        Market Cap (million EUR)                                           16
        Enterprise Value (million EUR)                                     13
        Shares Outstanding (million)                                        7
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Sep 03, 2012         curasan Obtains Japanese Patent For Block
                                                                                                           Forms
                                                                                      Jun 18, 2012         Curasan Receives European Approval For
                                                                                                           Screw In Dental Bone Regeneration Materials
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




curasan AG (CUR) - Financial and Strategic SWOT Analysis                                                                       Reference Code: GDME13733FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       curasan AG - Key Facts ..................................................................................................................................................................... 5
       curasan AG - Key Employees ............................................................................................................................................................ 6
       curasan AG - Key Employee Biographies .......................................................................................................................................... 7
       curasan AG - Major Products and Services........................................................................................................................................ 8
       curasan AG - Medical Equipment Pipeline Products Data.................................................................................................................. 9
          curasan AG Pipeline Products by Equipment Type ........................................................................................................................ 9
          curasan AG Pipeline Products by Development Stage ................................................................................................................. 11
       curasan AG - History ........................................................................................................................................................................ 13
       curasan AG - Locations And Subsidiaries ........................................................................................................................................ 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       curasan AG - Key Manufacturing Facilities....................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       curasan AG - Business Description .................................................................................................................................................. 18
       curasan AG - SWOT Analysis .......................................................................................................................................................... 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          curasan AG - Strengths ................................................................................................................................................................ 19
             Strength - Product Offerings...................................................................................................................................................... 19
             Strength - Research and Development ..................................................................................................................................... 19
             Strength - Strategic Agreements ............................................................................................................................................... 19
          curasan AG - Weaknesses ........................................................................................................................................................... 19
             Weakness - Dependence on End Market .................................................................................................................................. 19
             Weakness - Financial Performance .......................................................................................................................................... 20
          curasan AG - Opportunities .......................................................................................................................................................... 20
             Opportunity - Emerging Economies........................................................................................................................................... 20
             Opportunity - Product Launches ................................................................................................................................................ 20
             Opportunity - Wound Care Management Market ....................................................................................................................... 20
          curasan AG - Threats.................................................................................................................................................................... 20
             Threat - Risk of Product Obsolescence ..................................................................................................................................... 20
             Threat - Cost Containment Pressures ....................................................................................................................................... 20
             Threat - Government Regulations ............................................................................................................................................. 21
       curasan AG - Key Competitors ......................................................................................................................................................... 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance....................................................................
								
To top